317 related articles for article (PubMed ID: 19275700)
1. Drug targets in herpes simplex and Epstein Barr Virus infections.
Billaud G; Thouvenot D; Morfin F
Infect Disord Drug Targets; 2009 Apr; 9(2):117-25. PubMed ID: 19275700
[TBL] [Abstract][Full Text] [Related]
2. Novel targets for the development of anti-herpes compounds.
Greco A; Diaz JJ; Thouvenot D; Morfin F
Infect Disord Drug Targets; 2007 Mar; 7(1):11-8. PubMed ID: 17346207
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses.
Pagano JS; Datta AK
Am J Med; 1982 Jul; 73(1A):18-26. PubMed ID: 6285710
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine on herpes simplex virus and Epstein-Barr virus in a dually infected human lymphoblastoid cell line.
van der Horst CM; Lin JC; Raab-Traub N; Smith MC; Pagano JS
J Virol; 1987 Feb; 61(2):607-10. PubMed ID: 3027389
[TBL] [Abstract][Full Text] [Related]
5. [Prevention and therapy of herpesvirus infections].
Abb J
Zentralbl Bakteriol Mikrobiol Hyg B; 1985 Feb; 180(2-3):107-20. PubMed ID: 2986378
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
Drosu NC; Edelman ER; Housman DE
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapies for herpes viral infections (types 1 - 8).
Chakrabarty A; Pang KR; Wu JJ; Narvaez J; Rauser M; Huang DB; Beutner KR; Tyring SK
Expert Opin Emerg Drugs; 2004 Nov; 9(2):237-56. PubMed ID: 15571482
[TBL] [Abstract][Full Text] [Related]
8. A new promising candidate to overcome drug resistant herpes simplex virus infections.
Zinser E; Krawczyk A; Mühl-Zürbes P; Aufderhorst U; Draßner C; Stich L; Zaja M; Strobl S; Steinkasserer A; Heilingloh CS
Antiviral Res; 2018 Jan; 149():202-210. PubMed ID: 29155164
[TBL] [Abstract][Full Text] [Related]
9. Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.
Voigt S; Hofmann J; Edelmann A; Sauerbrei A; Kühl JS
Transpl Infect Dis; 2016 Oct; 18(5):791-794. PubMed ID: 27482652
[TBL] [Abstract][Full Text] [Related]
10. Novel Therapeutics for Epstein⁻Barr Virus.
Andrei G; Trompet E; Snoeck R
Molecules; 2019 Mar; 24(5):. PubMed ID: 30871092
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus infections: prospects for treatment.
Gershburg E; Pagano JS
J Antimicrob Chemother; 2005 Aug; 56(2):277-81. PubMed ID: 16006448
[TBL] [Abstract][Full Text] [Related]
12. Stromal keratitis and anterior uveitis due to herpes simplex virus-2 in a young child.
Inoda S; Wakakura M; Hirata J; Nakazato N; Toyo-Oka Y
Jpn J Ophthalmol; 2001; 45(6):618-21. PubMed ID: 11754904
[TBL] [Abstract][Full Text] [Related]
13. [New targets for new anti-herpes drugs].
Morfin F; Frobert E; Calle A; Thouvenot D; Diaz JJ; Greco A
Virologie (Montrouge); 2007 Dec; 11(6):423-432. PubMed ID: 36131465
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy of herpes simplex.
Snoeck R
Int J Antimicrob Agents; 2000 Oct; 16(2):157-9. PubMed ID: 11053800
[TBL] [Abstract][Full Text] [Related]
15. 5-(1-Substituted) alkyl pyrimidine nucleosides as antiviral (herpes) agents.
Kumar R
Curr Med Chem; 2004 Oct; 11(20):2749-66. PubMed ID: 15544474
[TBL] [Abstract][Full Text] [Related]
16. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.
James SH; Prichard MN
Curr Opin Virol; 2014 Oct; 8():54-61. PubMed ID: 25036916
[TBL] [Abstract][Full Text] [Related]
17. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management.
Piret J; Boivin G
Curr Opin Infect Dis; 2016 Dec; 29(6):654-662. PubMed ID: 27306564
[TBL] [Abstract][Full Text] [Related]
18. Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient.
Schnipper LE; Crumpacker CS; Marlowe SI; Kowalsky P; Hershey BJ; Levin MJ
Am J Med; 1982 Jul; 73(1A):387-92. PubMed ID: 6285729
[TBL] [Abstract][Full Text] [Related]
19. Novel agents and strategies to treat herpes simplex virus infections.
Kleymann G
Expert Opin Investig Drugs; 2003 Feb; 12(2):165-83. PubMed ID: 12556212
[TBL] [Abstract][Full Text] [Related]
20. Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner.
Huang WY; Su YH; Yao HW; Ling P; Tung YY; Chen SH; Wang X; Chen SH
J Gen Virol; 2010 Mar; 91(Pt 3):591-8. PubMed ID: 19906941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
